Page last updated: 2024-09-04

moxifloxacin and ethambutol

moxifloxacin has been researched along with ethambutol in 85 studies

Compound Research Comparison

Studies (moxifloxacin)	Trials (moxifloxacin)	Recent Studies (post-2010) (moxifloxacin)	Studies (ethambutol)	Trials (ethambutol)	Recent Studies (post-2010) (ethambutol)
3,157	552	1,690	4,454	366	1,143

Research

Studies (85)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	16 (18.82)	29.6817
2010's	54 (63.53)	24.3611
2020's	15 (17.65)	2.80

Authors

Authors	Studies
Cho, SH; Franzblau, SG; Hwang, CH; Pauli, GF; Wan, B; Warit, S	1
Andricopulo, AD; Moda, TL; Montanari, CA	1
Lombardo, F; Obach, RS; Waters, NJ	1
Aarnoutse, RE; Boeree, MJ; Kibiki, GS; Kisanga, ER; van den Boogaard, J	1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV	1
Angulo-Barturen, I; Beltrán, M; Cáceres, N; Cardona, PJ; García, JI; García-Bustos, JF; Rullas, J	1
Khanna, A; Pareek, PK; Raj, VS; Rattan, A; Saini, KS; Sharma, P; Singh, H; Sood, R; Tarai, B; Upadhyay, DJ	1
Barry, CE; Dartois, V	1
Bobesh, KA; Jeankumar, VU; Renuka, J; Shruti, SK; Sridevi, JP; Sriram, D; Yogeeswari, P	1
Babu, KS; Jeankumar, VU; Reddy, KI; Renuka, J; Shravan, M; Sridevi, JP; Srihari, K; Sriram, D; Yogeeswari, P	1
Devi, PB; Samala, G; Saxena, S; Sridevi, JP; Sriram, D; Yogeeswari, P	1
Bobesh, KA; Kulkarni, P; Renuka, J; Srilakshmi, RR; Sriram, D; Yellanki, S; Yogeeswari, P	1
Devi, PB; Meda, N; Samala, G; Saxena, S; Sriram, D; Yogeeswari, P	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Bobesh, KA; Gunda, S; Jeankumar, VU; Reshma, RS; Saxena, S; Sriram, D; Yogeeswari, P	1
Brindha Devi, P; Gunda, S; Samala, G; Saxena, S; Sriram, D; Yogeeswari, P	1
Abbadi, BL; Back, DF; Basso, LA; Campos, MM; Giacobbo, BC; Grams, ES; Machado, P; Pissinate, K; Rodrigues-Junior, V; Santos, DS; Sperotto, N; Subtil, FT; Trindade, RV; Villela, AD	1
Malapati, P; Meda, N; Nallangi, R; Reshma Srilakshmi, R; Siva Krishna, V; Sriram, D	1
Krishna, VS; Malapati, P; Nallangi, R; Srilakshmi, RR; Sriram, D	1
Bai, L; Deng, JL; Gao, F; Lv, ZS; Wang, Y; Xu, Z; Zhang, F; Zhao, SJ	1
da Silva Emery, F; de Melo, SMG; Fumagalli, F; Pavan, FR; Ribeiro, CM; Solcia, MC	1
Bishai, WR; Duan, G; Gunosewoyo, H; Liu, LL; Lun, S; Tang, J; Xiao, S; Yang, F; Yu, LF; Zhang, W	1
Bangalore, PK; Bollikanda, RK; Choudante, PC; Kantevari, S; Misra, S; Sridhar, B; Sriram, D; Vagolu, SK; Veeragoni, DK	1
Krishna, VS; Sirim, MM; Sriram, D; Unsal Tan, O	1
George, SE; Guddat, LW; Krishna, VS; Nallangi, R; Rekha, EM; Sai Prasad, DV; Sriram, D; Zheng, S	1
Aralar, P; Bermudez, LE; Inderlied, CB; Kolonoski, P; Petrofsky, M; Wu, M; Young, LS	1
Cheon, SH; Dietze, R; Ellner, JJ; Hise, AG; Landen, K; Palaci, M; Phillips, M; Ribeiro, FC; Song, HY; Vinhas, S; Wallis, RS	1
Binstock, P; Keating, M; Kontoyiannis, DP; Nannini, EC; Samonis, G	1
Bermudez, LE; Inderlied, CB; Kolonoski, P; Petrofsky, M; Wu, M; Young, LS	1
Ader, F; Bernard, L; Carlier, R; Perronne, C; Salomon, J; Toubiana, J	1
Burman, WJ; Chaisson, RE; Choudhri, S; Daley, CL; Engle, M; Goldberg, S; Johnson, JL; Mosher, AW; Munsiff, SS; Muzanye, G; Vernon, A; Zhao, Z	1
Bishai, WR; Cezar, MC; Chaisson, RE; Chaudhary, MA; Conde, MB; De Souza, GR; Efron, A; Graça, NP; Kritski, AL; Loredo, C; Ram, M	1
Chen, YC; Ho, CC; Hu, FC; Luh, KT; Yang, PC; Yu, CJ	1
Agnihotri, SP; Gupta, P; Gupta, S; Jain, NK; Sharma, KK	1
Chang, KC; Leung, CC	1
Bergmann, JF; Delcey, V; Raskine, L; Sanson-Le-Pors, MJ; Sellier, P	1
Gumbo, T	1
Burman, W; Duran, P; Engle, M; Goldberg, S; Johnson, JL; Mugerwa, RD; Muzanye, G; Padayatchi, N; Prihoda, TJ; Sturm, AW; Weiner, M	1
Deshpande, D; Gumbo, T	1
Dannecker, G; Hess, S; Hospach, T; Magdorf, K; Nossal, R; Uhlemann, F	1
Achawal, S; Anderson, G; Lee, WY; Ling, M; Thaker, HK	1
Colucci, G; Silzle, T; Solenthaler, M	1
Braissant, O; Daniels, AU; Howell, M; Wirz, D	1
Hamilton, CD; Holland, DP; Sanders, GD; Stout, JE	1
Cole, ST; Hartkoorn, RC; Lechartier, B	1
Hong, G; Jeon, K; Jeong, BH; Kim, CK; Kim, SY; Koh, WJ; Kwon, OJ; Lee, SH; Park, HY; Shin, SJ	1
Alland, D; Armakovitch, S; Armstrong, DT; Barry, CE; Chien, G; Cho, SN; Dorman, SE; Ellner, JJ; Joloba, ML; Lee, J; Mboowa, G; Mumbowa, F; Nakayita, G; Namaganda, C; Park, JA; Ssengooba, W; Via, LE; Yu, Y	1
Chouiter, A; Lebowitz, D; Malinverni, R; Wolter, L; Zenklusen, C	1
Blyth, CC; Colby, S; Fagan, JM; Francis, JR; Waring, J	1
Crook, AM; Gillespie, SH; McHugh, TD; Mendel, CM; Meredith, SK; Murray, SR; Nunn, AJ; Pappas, F; Phillips, PP	1
Chiang, CY; Madan, J; Meredith, SK; Nunn, AJ; Phillips, PP; Rusen, ID; Squire, SB; Torrea, G; Van Deun, A	1
de Droogh, E; Groenen, G; Mathys, V; Soetaert, K; van de Vyvere, M	1
Bateson, AL; Butcher, PD; Charalambous, S; Churchyard, GJ; Clouting, HE; Coleman, D; Geldenhuys, H; Harrison, TS; Hatherill, M; Jindani, A; Magweta, L; McHugh, TD; McIlleron, HM; Mitchison, DA; Mungofa, S; Nunn, AJ; Nyirenda, S; Phillips, PP; Shah, NA; Shepherd, J; van Dijk, JH; Zizhou, S; Zvada, SP	1
Adelakun, A; Bhatnagar, V; Chen, Q; Emadi, A; Farshidpour, M; Holtzman, N; Kendall, T; Stevenson, B	1
Burger, DA; Conradie, A; Dawson, R; Diacon, AH; Donald, PR; Eisenach, K; Everitt, D; Ive, P; Mendel, CM; Ntinginya, NE; Page-Shipp, L; Pym, A; Reither, K; Schall, R; Spigelman, M; van Niekerk, C; Variava, E; Venter, A; von Groote-Bidlingmaier, F	1
Amoroso, A; Britt, EJ; Burke, AP; Franco, M; Reed, RM	1
Agrawal, R; Barraclough, C; Pavesio, CE; Potter, J; Rahman, F; Westcott, M; White, V	1
Cegiełkowska, M; Czopowicz, M; Dolka, B; Dolka, I; Ledwoń, A; Szeleszczuk, P	1
Blackmore, T; McNaughton, A; McNaughton, H	1
Centis, R; D'Ambrosio, L; Fuentes, Z; Migliori, GB; Sotgiu, G; Tiberi, S; Zumla, A	1
Aarnoutse, R; Boeree, MJ; Charalambous, S; Churchyard, G; Colbers, A; Dawson, R; Diacon, AH; Gillespie, SH; Hanekom, M; Heinrich, N; Henne, S; Hoelscher, M; Hunt, RD; Kibiki, GS; Manyama, C; Mekota, A; Minja, LT; Mpagama, SG; Mtafya, B; Narunsky, K; Ntinginya, NE; Phillips, PPJ; Rehal, S; Reither, K; Sanne, I; Semvua, HH; van Balen, GP; Venter, A; Wallis, RS	1
Mendel, C; Murray, S; Spigelman, M	1
Chen, YH; Huang, CH; Kuo, CY; Lu, PL; Wang, WH	1
Cohen, L; Guarner, J; Hunt, WR	1
Deshpande, D; Gumbo, T; Sherman, CM; Srivastava, S	1
Clifton, DA; Crook, DW; Iqbal, Z; Niehaus, KE; Peto, TEA; Smith, EG; Walker, AS; Walker, TM; Wilson, DJ; Yang, Y; Zhu, T	1
Caminero Luna, JA; Cerezo Lajas, A; de Miguel Díez, J; Rodríguez Guzmán, MDC	1
Bax, HI; de Knegt, GJ; de Steenwinkel, JEM; Mourik, BC; Simonsson, USH; Svensson, RJ; Verbon, A	1
Carrera-Pineda, R; Garcia-Luna, RC; Soto-Cabrera, E; Villamil-Osorio, LV	1
Coates, AR; Davies, GR; Gillespie, SH; Hu, Y; Liu, Y; Pertinez, H	1
Amukoye, EI; Crook, AM; Dawson, R; Diacon, AH; Gillespie, SH; Hanekom, M; McHugh, TD; Mendel, CM; Meredith, SK; Murphy, ME; Murthy, SE; Nunn, AJ; Phillips, PPJ; Singh, KP; Spigelman, M; Tweed, CD; Wills, GH	1
Cao, P; Doan, TN; Emeto, TI; McBryde, ES; McCaw, JM	1
Chigutsa, E; Deshpande, D; Gumbo, T; Magombedze, G; McIlleron, H; Pasipanodya, JG; Srivastava, S; Visser, ME	1
Ajitkumar, P; Nair, RR; Paul, A; Pradhan, A; Sebastian, J; Swaminath, S	1
Bozeman, L; Burman, WJ; Chaisson, RE; Chang, KC; Chen, M; Cotton, M; Dooley, KE; Dorman, SE; Engle, M; Feng, PJ; Fletcher, CV; Goldberg, SV; Ha, P; Heilig, CM; Johnson, JL; Kurbatova, EV; Lessem, E; Metchock, B; Miro, JM; Nahid, P; Nhung, NV; Pettit, AC; Phillips, PPJ; Podany, AT; Purfield, AE; Robergeau, K; Samaneka, W; Scott, NA; Sizemore, E; Swindells, S; Vernon, A; Weiner, M	1
Alameer, R; Almaghrabi, RS; Almohaizeie, A; Alrajhi, AA; Alshehri, N; Nizami, I; Omrani, AS	1
Ahmad, N; Atif, M; Ghafoor, A; Iqbal, Q; Khan, S; Latif, A; Saleem, F; Wahid, A	1
Bishai, W; Dawson, R; De Jager, V; Diacon, A; Donahue, K; Fletcher, CV; Hafner, R; Hogg, E; Miyahara, S; Sun, X; Swindells, S; Urbanowski, M	1
Chen, W; Cheng, NC; Fang, G; Hu, CM; Huang, LL; Xie, WP	1
Bader, JS; Danchik, C; Hoover, L; Karakousis, PC; Matern, WM; Parker, H	1
Guo, Y; Liu, H; Sha, W; Shen, H; Shen, X; Tan, G; Wu, X; Wu, Z; Yang, J; Yu, F	1
Guo, Y; Huang, C; Sha, W; Tan, G; Wu, X; Yang, J; Yu, F	1
Du, Y; Huang, H; Huang, J; Jia, J; Nong, Y; Song, W; Tan, Q; Xiao, X; Xu, J; Zhong, R; Zhu, R	1
Berge, I; Bogdanova, I; Freimane, L; Norvaiša, I; Ozere, I; Ranka, R; Sadovska, D; Vaivode, A; Vīksna, A	1
Aalhoul, F; Cotton, F; Fage, D	1

Reviews

6 review(s) available for moxifloxacin and ethambutol

Article	Year
New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:3 Topics: Animals; Antitubercular Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Design; Drug Evaluation, Preclinical; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Mycobacterium tuberculosis; Rifamycins; Tuberculosis	2009
A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis. Bioorganic & medicinal chemistry letters, 2013, Sep-01, Volume: 23, Issue:17 Topics: Animals; Antitubercular Agents; Drug Discovery; Humans; Lung; Mycobacterium tuberculosis; Tuberculosis	2013
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Fluoroquinolone-isatin hybrids and their biological activities. European journal of medicinal chemistry, 2019, Jan-15, Volume: 162 Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antineoplastic Agents; Antitubercular Agents; Antiviral Agents; Fluoroquinolones; Humans; Isatin; Structure-Activity Relationship	2019
Pharmacokinetic/pharmacodynamic-based treatment of disseminated Mycobacterium avium. Future microbiology, 2011, Volume: 6, Issue:4 Topics: Anti-Bacterial Agents; Aza Compounds; Ethambutol; Fluoroquinolones; Humans; Macrolides; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Quinolines; Treatment Outcome	2011
The first report of co-existence of pulmonary tuberculosis and lung malignancy in a kidney transplant recipient: a case report and literature review. BMC infectious diseases, 2021, Jul-01, Volume: 21, Issue:1 Topics: Adenocarcinoma; China; Ethambutol; Fluorodeoxyglucose F18; Humans; Image-Guided Biopsy; Isoniazid; Kidney Transplantation; Lung; Lung Neoplasms; Male; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Positron Emission Tomography Computed Tomography; Thoracic Surgery, Video-Assisted; Treatment Outcome; Tuberculosis, Pulmonary	2021

Trials

9 trial(s) available for moxifloxacin and ethambutol

Article	Year
Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. American journal of respiratory and critical care medicine, 2006, Aug-01, Volume: 174, Issue:3 Topics: Adult; Africa; Antitubercular Agents; Aza Compounds; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Female; Fluoroquinolones; Humans; Male; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Sputum; Tuberculosis, Pulmonary; United States	2006
Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet (London, England), 2009, Apr-04, Volume: 373, Issue:9670 Topics: Adult; Antitubercular Agents; Aza Compounds; Brazil; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Female; Fluoroquinolones; Humans; Isoniazid; Kaplan-Meier Estimate; Logistic Models; Male; Moxifloxacin; Multivariate Analysis; Pyrazinamide; Quinolines; Rifampin; Sputum; Time Factors; Treatment Outcome; Tuberculosis, Pulmonary	2009
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17 Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Female; Fluoroquinolones; HIV Seropositivity; Humans; Isoniazid; Kaplan-Meier Estimate; Male; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary; Young Adult	2014
Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial. Trials, 2014, Sep-09, Volume: 15 Topics: Antitubercular Agents; Bangladesh; Clinical Protocols; Clofazimine; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Fluoroquinolones; Humans; Isoniazid; Kanamycin; Moxifloxacin; Prothionamide; Pyrazinamide; Research Design; Time Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2014
High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17 Topics: Adolescent; Adult; Antitubercular Agents; Coinfection; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Female; Fluoroquinolones; HIV Seropositivity; Humans; Isoniazid; Kaplan-Meier Estimate; Male; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary; Young Adult	2014
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pul Lancet (London, England), 2015, May-02, Volume: 385, Issue:9979 Topics: Adolescent; Adult; Antitubercular Agents; Colony Count, Microbial; Drug Therapy, Combination; Ethambutol; Female; Fluoroquinolones; Humans; Isoniazid; Male; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Rifampin; South Africa; Sputum; Tanzania; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult	2015
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. The Lancet. Infectious diseases, 2017, Volume: 17, Issue:1 Topics: Adamantane; Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Ethylenediamines; Female; Fluoroquinolones; Humans; Isoniazid; Male; Moxifloxacin; Pyrazinamide; Rifampin; South Africa; Tanzania; Tuberculosis, Pulmonary	2017
High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial. Contemporary clinical trials, 2020, Volume: 90 Topics: Adolescent; Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, Combination; Equivalence Trials as Topic; Ethambutol; Female; HIV Infections; Humans; Male; Middle Aged; Moxifloxacin; Rifampin; Tuberculosis, Pulmonary; Young Adult	2020
Assessing whether isoniazid is essential during the first 14 days of tuberculosis therapy: a phase 2a, open-label, randomised controlled trial. The Lancet. Microbe, 2020, Volume: 1, Issue:2 Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Humans; Isoniazid; Moxifloxacin; Pyrazinamide; Rifampin; Tuberculosis	2020

Other Studies

70 other study(ies) available for moxifloxacin and ethambutol

Article	Year
Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:4 Topics: Anti-Bacterial Agents; Antitubercular Agents; DNA, Bacterial; Drug Evaluation, Preclinical; Mycobacterium tuberculosis; Oxygen	2007
Hologram QSAR model for the prediction of human oral bioavailability. Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24 Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship	2007
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Physicochemical determinants of human renal clearance. Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15 Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight	2009
Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:5 Topics: Acetamides; Animals; Antitubercular Agents; Aza Compounds; Disease Models, Animal; Drug Discovery; Ethambutol; Fluoroquinolones; Immunocompetence; Inhalation Exposure; Isoniazid; Linezolid; Mice; Mice, Inbred C57BL; Moxifloxacin; Oxazolidinones; Pyrazinamide; Quinolines; Reproducibility of Results; Rifampin; Tuberculosis, Pulmonary	2010
Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:11 Topics: Amikacin; Antitubercular Agents; Bacterial Proteins; Capreomycin; DNA Gyrase; DNA Mutational Analysis; DNA-Directed RNA Polymerases; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; India; Isoniazid; Kanamycin; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Point Mutation; Polymerase Chain Reaction; Rifampin	2010
Extending the N-linked aminopiperidine class to the mycobacterial gyrase domain: pharmacophore mapping from known antibacterial leads. European journal of medicinal chemistry, 2014, Oct-06, Volume: 85 Topics: Anti-Bacterial Agents; DNA Gyrase; Drug Design; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitrogen; Piperidines; Protein Structure, Tertiary; Structure-Activity Relationship; Topoisomerase II Inhibitors	2014
Design, synthesis, biological evaluation of substituted benzofurans as DNA gyraseB inhibitors of Mycobacterium tuberculosis. Bioorganic & medicinal chemistry, 2014, Sep-01, Volume: 22, Issue:17 Topics: Animals; Antitubercular Agents; Benzofurans; Cell Line; DNA Gyrase; Dose-Response Relationship, Drug; Drug Design; Mice; Microbial Sensitivity Tests; Molecular Docking Simulation; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship; Topoisomerase II Inhibitors	2014
Design and development of novel Mycobacterium tuberculosis L-alanine dehydrogenase inhibitors. European journal of medicinal chemistry, 2015, Mar-06, Volume: 92 Topics: Alanine Dehydrogenase; Animals; Cell Line; Dose-Response Relationship, Drug; Drug Design; Enzyme Inhibitors; Macrophages; Mice; Models, Molecular; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship	2015
Replacement of cardiotoxic aminopiperidine linker with piperazine moiety reduces cardiotoxicity? Mycobacterium tuberculosis novel bacterial topoisomerase inhibitors. Bioorganic & medicinal chemistry, 2016, Jan-01, Volume: 24, Issue:1 Topics: Animals; Antitubercular Agents; Atrioventricular Block; Cardiotoxicity; DNA Gyrase; Enzyme Assays; Ether-A-Go-Go Potassium Channels; Heart Rate; Mycobacterium tuberculosis; Naphthyridines; Novobiocin; Piperazines; Terfenadine; Topoisomerase II Inhibitors; Zebrafish; Zebrafish Proteins	2016
Design, synthesis and biological evaluation of imidazo[2,1-b]thiazole and benzo[d]imidazo[2,1-b]thiazole derivatives as Mycobacterium tuberculosis pantothenate synthetase inhibitors. Bioorganic & medicinal chemistry, 2016, Mar-15, Volume: 24, Issue:6 Topics: Animals; Anti-Bacterial Agents; Dose-Response Relationship, Drug; Drug Design; Enzyme Inhibitors; Imidazoles; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Peptide Synthases; Structure-Activity Relationship; Thiazoles; Zebrafish	2016
Design and development of new class of Mycobacterium tuberculosisl-alanine dehydrogenase inhibitors. Bioorganic & medicinal chemistry, 2016, 09-15, Volume: 24, Issue:18 Topics: Alanine Dehydrogenase; Antitubercular Agents; Carbon-13 Magnetic Resonance Spectroscopy; Crystallography, X-Ray; Drug Design; Molecular Structure; Mycobacterium tuberculosis; Proton Magnetic Resonance Spectroscopy; Spectrometry, Mass, Electrospray Ionization; Structure-Activity Relationship	2016
Anti-tubercular activities of 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine analogues endowed with high activity toward non-replicative Mycobacterium tuberculosis. Bioorganic & medicinal chemistry, 2016, 11-01, Volume: 24, Issue:21 Topics: Alanine Dehydrogenase; Antitubercular Agents; Dose-Response Relationship, Drug; Enzyme Inhibitors; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Pyrimidines; Structure-Activity Relationship; Thiophenes	2016
New insights into the SAR and drug combination synergy of 2-(quinolin-4-yloxy)acetamides against Mycobacterium tuberculosis. European journal of medicinal chemistry, 2017, Jan-27, Volume: 126 Topics: Acetamides; Animals; Antitubercular Agents; Drug Resistance, Bacterial; Drug Synergism; Humans; Macrophages; Mice; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Quinolines; RAW 264.7 Cells; Structure-Activity Relationship	2017
Lead identification and optimization of bacterial glutamate racemase inhibitors. Bioorganic & medicinal chemistry, 2018, 01-01, Volume: 26, Issue:1 Topics: Amino Acid Isomerases; Animals; Antitubercular Agents; Cell Survival; Dose-Response Relationship, Drug; Enzyme Inhibitors; Mice; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; RAW 264.7 Cells; Structure-Activity Relationship	2018
Identification and development of benzoxazole derivatives as novel bacterial glutamate racemase inhibitors. European journal of medicinal chemistry, 2018, Feb-10, Volume: 145 Topics: Amino Acid Isomerases; Animals; Anti-Bacterial Agents; Benzoxazoles; Biofilms; Cell Survival; Dose-Response Relationship, Drug; Enzyme Inhibitors; Kinetics; Mice; Microbial Sensitivity Tests; Molecular Docking Simulation; Molecular Structure; Mycobacterium; RAW 264.7 Cells; Structure-Activity Relationship; Zebrafish	2018
Exploiting the furo[2,3-b]pyridine core against multidrug-resistant Mycobacterium tuberculosis. Bioorganic & medicinal chemistry letters, 2019, 04-15, Volume: 29, Issue:8 Topics: Amination; Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Furans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Pyridines; Structure-Activity Relationship	2019
Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis. Part II. Journal of medicinal chemistry, 2019, 04-11, Volume: 62, Issue:7 Topics: Animals; Antitubercular Agents; Chlorocebus aethiops; Coumarins; Crystallography, X-Ray; Drug Resistance, Bacterial; Enzyme Inhibitors; Humans; Microbial Sensitivity Tests; Molecular Docking Simulation; Mycobacterium tuberculosis; Polyketide Synthases; Structure-Activity Relationship; Vero Cells	2019
Usnic Acid Enaminone-Coupled 1,2,3-Triazoles as Antibacterial and Antitubercular Agents. Journal of natural products, 2020, 01-24, Volume: 83, Issue:1 Topics: Anti-Bacterial Agents; Antitubercular Agents; Bacillus subtilis; Benzofurans; Lichens; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Triazoles	2020
Novel benzimidazole-acrylonitrile hybrids and their derivatives: Design, synthesis and antimycobacterial activity. European journal of medicinal chemistry, 2020, Feb-15, Volume: 188 Topics: Acrylonitrile; Anti-Bacterial Agents; Benzimidazoles; Dose-Response Relationship, Drug; Drug Design; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship	2020
Design and development of ((4-methoxyphenyl)carbamoyl) (5-(5-nitrothiophen-2-yl)-1,3,4-thiadiazol-2-yl)amide analogues as Mycobacterium tuberculosis ketol-acid reductoisomerase inhibitors. European journal of medicinal chemistry, 2020, May-01, Volume: 193 Topics: Amides; Animals; Antitubercular Agents; Biofilms; Cell Line; Dose-Response Relationship, Drug; Drug Development; Enzyme Inhibitors; HEK293 Cells; Humans; Ketol-Acid Reductoisomerase; Macrophages; Mice; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship	2020
Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium. Antimicrobial agents and chemotherapy, 2001, Volume: 45, Issue:1 Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antitubercular Agents; Aza Compounds; Azithromycin; Drug Interactions; Drug Therapy, Combination; Ethambutol; Female; Fluoroquinolones; Macrophages; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Quinolines; Rifabutin	2001
A whole blood bactericidal assay for tuberculosis. The Journal of infectious diseases, 2001, Apr-15, Volume: 183, Issue:8 Topics: Anti-Infective Agents; Antitubercular Agents; Aza Compounds; Blood; Blood Bactericidal Activity; Culture Media; Ethambutol; Fluoroquinolones; Humans; Isoniazid; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Pyrazinamide; Quinolines; Rifampin	2001
Successful treatment of refractory disseminated Mycobacterium avium complex infection with the addition of linezolid and mefloquine. The Journal of infection, 2002, Volume: 44, Issue:3 Topics: Acetamides; Anti-Bacterial Agents; Aza Compounds; Clarithromycin; Drug Therapy, Combination; Ethambutol; Fatal Outcome; Fluoroquinolones; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Linezolid; Male; Mefloquine; Middle Aged; Moxifloxacin; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Oxazolidinones; Quinolines	2002
Mefloquine, moxifloxacin, and ethambutol are a triple-drug alternative to macrolide-containing regimens for treatment of Mycobacterium avium disease. The Journal of infectious diseases, 2003, Jun-15, Volume: 187, Issue:12 Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antimalarials; Aza Compounds; Clarithromycin; Disease Models, Animal; Drug Resistance, Bacterial; Drug Therapy, Combination; Ethambutol; Fluoroquinolones; Mefloquine; Mice; Moxifloxacin; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Quinolines	2003
[Cervical spondylodiscitis: one pathogen may hide another]. Medecine et maladies infectieuses, 2006, Volume: 36, Issue:1 Topics: Anti-Bacterial Agents; Antitubercular Agents; Aza Compounds; Cervical Vertebrae; Cholecystitis; Discitis; Disease Progression; Drug Therapy, Combination; Escherichia coli; Escherichia coli Infections; Ethambutol; Fluoroquinolones; France; Humans; Immobilization; Isoniazid; Male; Middle Aged; Morocco; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Quinolines; Radiography; Rifampin; Tuberculosis, Spinal	2006
Safety of fluoroquinolone use in patients with hepatotoxicity induced by anti-tuberculosis regimens. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009, Jun-01, Volume: 48, Issue:11 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Anti-Bacterial Agents; Antitubercular Agents; Aspartate Aminotransferases; Aza Compounds; Ethambutol; Female; Fluoroquinolones; Hepatic Insufficiency; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines; Streptomycin; Treatment Outcome; Tuberculosis; Young Adult	2009
Extensively drug resistance (XDR) tb is not always fatal. The Indian journal of tuberculosis, 2009, Volume: 56, Issue:1 Topics: Adult; Aminosalicylic Acid; Antitubercular Agents; Aza Compounds; Capreomycin; Clarithromycin; Clofazimine; Drug Therapy, Combination; Ethambutol; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; India; Injections; Male; Moxifloxacin; Quinolines; Sputum; Treatment Outcome	2009
Moxifloxacin versus ethambutol in initial tuberculosis treatment. Lancet (London, England), 2009, Jun-27, Volume: 373, Issue:9682 Topics: Analysis of Variance; Antitubercular Agents; Aza Compounds; Ethambutol; Fluoroquinolones; Humans; Logistic Models; Moxifloxacin; Odds Ratio; Quinolines; Sputum; Tuberculosis, Pulmonary	2009
Moxifloxacin versus ethambutol in initial tuberculosis treatment. Lancet (London, England), 2009, Jun-27, Volume: 373, Issue:9682 Topics: Antitubercular Agents; Aza Compounds; Drug Administration Schedule; Ethambutol; Fluoroquinolones; Humans; Medication Adherence; Moxifloxacin; Patient Selection; Practice Guidelines as Topic; Quinolines; Sputum; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2009
New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:4 Topics: Antitubercular Agents; Aza Compounds; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Ethambutol; Fluoroquinolones; Humans; In Vitro Techniques; Isoniazid; Microbial Sensitivity Tests; Models, Biological; Monte Carlo Method; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Quinolines; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant	2010
Evaluation of time to detection of Mycobacterium tuberculosis in broth culture as a determinant for end points in treatment trials. Journal of clinical microbiology, 2010, Volume: 48, Issue:12 Topics: Adult; Antitubercular Agents; Aza Compounds; Bacteriological Techniques; Clinical Trials as Topic; Drug Monitoring; Ethambutol; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Time Factors; Tuberculosis	2010
Life-threatening disseminated tuberculosis as a complication of TNF-α blockade in an adolescent. European journal of pediatrics, 2011, Volume: 170, Issue:10 Topics: Acquired Hyperostosis Syndrome; Adalimumab; Adolescent; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antitubercular Agents; Aza Compounds; Drug Therapy, Combination; Dyspnea; Ethambutol; Female; Fluoroquinolones; Humans; Immunocompromised Host; Immunosuppressive Agents; Moxifloxacin; Quinolines; Severity of Illness Index; Shock, Septic; Treatment Outcome; Tuberculosis, Miliary; Tumor Necrosis Factor-alpha	2011
Isoniazid-resistant intracranial tuberculoma treated with a combination of moxifloxacin and first-line anti-tuberculosis medication. Journal of medical microbiology, 2011, Volume: 60, Issue:Pt 10 Topics: Antitubercular Agents; Aza Compounds; Biopsy; Brain; Cerebrospinal Fluid; Drug Resistance, Bacterial; Ethambutol; Female; Fluoroquinolones; Histocytochemistry; Humans; Isoniazid; Magnetic Resonance Imaging; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Quinolines; Rifampin; Tomography, X-Ray Computed; Treatment Outcome; Tuberculoma, Intracranial; Tuberculosis, Multidrug-Resistant; Young Adult	2011
Pyrazinamide-induced sideroblastic anemia. American journal of hematology, 2012, Volume: 87, Issue:3 Topics: 5-Aminolevulinate Synthetase; alpha-Thalassemia; Anemia, Sideroblastic; Antitubercular Agents; Aza Compounds; Bone Marrow; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Ethambutol; Female; Fluoroquinolones; Hemolysis; Humans; Isoniazid; Middle Aged; Moxifloxacin; Peritonitis, Tuberculous; Pyrazinamide; Pyridoxine; Quinolines; Rifampin	2012
Application of a microcalorimetric method for determining drug susceptibility in mycobacterium species. Journal of clinical microbiology, 2012, Volume: 50, Issue:1 Topics: Antitubercular Agents; Aza Compounds; Calorimetry; Ethambutol; Fluoroquinolones; Humans; Isoniazid; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium avium; Mycobacterium smegmatis; Mycobacterium tuberculosis; Quinolines	2012
Strategies for treating latent multiple-drug resistant tuberculosis: a decision analysis. PloS one, 2012, Volume: 7, Issue:1 Topics: Animals; Antitubercular Agents; Aza Compounds; Cost-Benefit Analysis; Decision Support Techniques; Drug Therapy; Drug Therapy, Combination; Ethambutol; Fluoroquinolones; Humans; Isoniazid; Markov Chains; Mice; Models, Theoretical; Moxifloxacin; Outcome Assessment, Health Care; Quality-Adjusted Life Years; Quinolines; Rifampin; Tuberculosis, Multidrug-Resistant	2012
In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:11 Topics: Adamantane; Antitubercular Agents; Aza Compounds; Diarylquinolines; Drug Combinations; Drug Synergism; Ethambutol; Ethylenediamines; Fluoroquinolones; Isoniazid; Meropenem; Microbial Sensitivity Tests; Microbial Viability; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Quinolines; Rifampin; Spiro Compounds; Thiazines; Thienamycins	2012
Treatment of refractory Mycobacterium avium complex lung disease with a moxifloxacin-containing regimen. Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:5 Topics: Aged; Anti-Bacterial Agents; Aza Compounds; Clarithromycin; Drug Resistance, Bacterial; Ethambutol; Female; Fluoroquinolones; Humans; Lung; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Quinolines; Rifampin; Sputum	2013
Sensititre MYCOTB MIC plate for testing Mycobacterium tuberculosis susceptibility to first- and second-line drugs. Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:1 Topics: Antitubercular Agents; Ethambutol; Fluoroquinolones; Isoniazid; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Rifampin	2014
TB determined: tuberculous osteomyelitis. The American journal of medicine, 2014, Volume: 127, Issue:3 Topics: Antitubercular Agents; Aza Compounds; Bone Neoplasms; Diagnosis, Differential; Drug Therapy, Combination; Ethambutol; Fluorodeoxyglucose F18; Fluoroquinolones; Humans; Lung; Magnetic Resonance Imaging; Male; Middle Aged; Moxifloxacin; Osteomyelitis; Positron-Emission Tomography; Quinolines; Radiopharmaceuticals; Rifampin; Spine; Tomography, X-Ray Computed; Tuberculosis, Osteoarticular	2014
Multidrug-resistant tuberculosis in Western Australia, 1998-2012. The Medical journal of Australia, 2014, Apr-07, Volume: 200, Issue:6 Topics: Adolescent; Adult; Antitubercular Agents; Aza Compounds; Case-Control Studies; Child; Drug Therapy, Combination; Ethambutol; Female; Fluoroquinolones; Hospitalization; Humans; Isoniazid; Male; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Quinolines; Retrospective Studies; Risk Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Western Australia; Young Adult	2014
False-positive rifampicin resistance on Xpert® MTB/RIF caused by a silent mutation in the rpoB gene. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2014, Volume: 18, Issue:10 Topics: Aged; Amikacin; Amino Acid Sequence; Antibiotics, Antitubercular; Bacterial Proteins; DNA-Directed RNA Polymerases; Drug Resistance, Multiple, Bacterial; Ethambutol; Ethionamide; Fluoroquinolones; Genotype; Humans; Isoniazid; Male; Molecular Sequence Data; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Phenotype; Pyrazinamide; Rifampin; Sensitivity and Specificity; Sputum; Tuberculosis, Pulmonary	2014
Diseases at the crossroads: chronic myelogenous leukemia and tuberculosis. Archives of Iranian medicine, 2015, Volume: 18, Issue:1 Topics: Adult; Antitubercular Agents; Dasatinib; Ethambutol; Female; Fluoroquinolones; Humans; Isoniazid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Moxifloxacin; Peritonitis, Tuberculous; Protein Kinase Inhibitors; Pyrazinamide; Pyrimidines; Thiazoles	2015
Pulmonary mycobacterial spindle cell pseudotumor in a lung transplant patient: progression without therapy and response to therapy. Transplant infectious disease : an official journal of the Transplantation Society, 2015, Volume: 17, Issue:3 Topics: Aged; Anti-Bacterial Agents; Azithromycin; Disease Progression; Ethambutol; Female; Fluoroquinolones; Humans; Immunocompromised Host; Lung; Lung Transplantation; Moxifloxacin; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Treatment Outcome	2015
Moxifloxacin: An Alternative to Ethambutol for the Treatment of Presumed Ocular Tuberculosis. Ocular immunology and inflammation, 2016, Volume: 24, Issue:5 Topics: Administration, Oral; Adult; Aged; Antitubercular Agents; Complementary Therapies; Ethambutol; Female; Fluoroquinolones; Glucocorticoids; Humans; Immunosuppressive Agents; Interferons; Male; Middle Aged; Moxifloxacin; Tuberculin Test; Tuberculosis, Ocular; Young Adult	2016
Multidrug therapy of Mycobacterium avium subsp. avium infection in experimentally inoculated budgerigars (Melopsittacus undulatus). Avian pathology : journal of the W.V.P.A, 2015, Volume: 44, Issue:6 Topics: Animals; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Ethambutol; Female; Fluoroquinolones; Galliformes; Male; Melopsittacus; Moxifloxacin; Mycobacterium avium; Tuberculosis, Avian	2015
Comprehensive cost of treating one patient with MDR/pre-XDR-TB in Wellington, New Zealand. The European respiratory journal, 2016, Volume: 48, Issue:4 Topics: Adult; Amikacin; Aminosalicylic Acid; Anti-Bacterial Agents; Antitubercular Agents; Bronchoscopy; Clofazimine; Depression; Drug Costs; Emigrants and Immigrants; Ethambutol; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Health Care Costs; Humans; India; Isoniazid; Linezolid; Male; Mediastinum; Microbial Sensitivity Tests; Moxifloxacin; New Zealand; Pyrazinamide; Radiography, Thoracic; Rifampin; Schizophrenia, Paranoid; Tuberculosis, Lymph Node; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pleural; Tuberculosis, Pulmonary	2016
Applicability of the shorter 'Bangladesh regimen' in high multidrug-resistant tuberculosis settings. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2017, Volume: 56 Topics: Antitubercular Agents; Clinical Protocols; Diarylquinolines; Drug Therapy, Combination; Ethambutol; Fluoroquinolones; Humans; Isoniazid; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Tuberculosis, Multidrug-Resistant; World Health Organization	2017
TB Alliance regimen development for multidrug-resistant tuberculosis. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2016, 12-01, Volume: 20, Issue:12 Topics: Antitubercular Agents; Clinical Protocols; Diarylquinolines; Dose-Response Relationship, Drug; Ethambutol; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; Isoniazid; Linezolid; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Randomized Controlled Trials as Topic; Research Design; Rifampin; Tuberculosis, Multidrug-Resistant	2016
Resistance to first- and second-line antituberculosis drugs in Southern Taiwan: Implications for empirical treatment. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2018, Volume: 51, Issue:1 Topics: Aminosalicylic Acid; Antitubercular Agents; Ethambutol; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Pyrazinamide; Streptomycin; Taiwan	2018
A novel presentation of Mycobacterium avium complex in a recipient of a lung transplant: a case report. Journal of medical case reports, 2017, Aug-28, Volume: 11, Issue:1 Topics: Aged; Antitubercular Agents; Ethambutol; Female; Fluoroquinolones; Graft Rejection; Humans; Immunosuppressive Agents; Lung; Lung Transplantation; Moxifloxacin; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Prednisone; Pulmonary Fibrosis; Rifampin; Tacrolimus; Tomography, X-Ray Computed; Tuberculosis, Pulmonary	2017
A 'shock and awe' thioridazine and moxifloxacin combination-based regimen for pulmonary Mycobacterium avium-intracellulare complex disease. The Journal of antimicrobial chemotherapy, 2017, Sep-01, Volume: 72, Issue:suppl_2 Topics: Anti-Bacterial Agents; Antipsychotic Agents; Azithromycin; Drug Therapy, Combination; Ethambutol; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Models, Biological; Monocytes; Moxifloxacin; Mycobacterium avium Complex; Thioridazine; THP-1 Cells	2017
Machine learning for classifying tuberculosis drug-resistance from DNA sequencing data. Bioinformatics (Oxford, England), 2018, 05-15, Volume: 34, Issue:10 Topics: Antitubercular Agents; Ciprofloxacin; Ethambutol; Humans; Isoniazid; Machine Learning; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Pyrazinamide; Rifampin; Sequence Analysis, DNA; Streptomycin; Tuberculosis, Multidrug-Resistant	2018
Antituberculosis Treatment in a Patient with Celiac Disease. Archivos de bronconeumologia, 2018, Volume: 54, Issue:6 Topics: Aged; Antitubercular Agents; Celiac Disease; Diarrhea; Diet, Gluten-Free; Drug Compounding; Drug Substitution; Drug Therapy, Combination; Ethambutol; Glutens; Hemoptysis; Humans; Isoniazid; Male; Metronidazole; Moxifloxacin; Pyrazinamide; Rifampin; Smoking; Tomography, X-Ray Computed; Tuberculosis, Pulmonary	2018
Improving treatment outcome assessment in a mouse tuberculosis model. Scientific reports, 2018, 04-09, Volume: 8, Issue:1 Topics: Administration, Oral; Animals; Antitubercular Agents; Disease Models, Animal; Drug Therapy, Combination; Ethambutol; Female; Genotype; Humans; Mice; Mice, Inbred BALB C; Models, Theoretical; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Treatment Outcome; Tuberculosis	2018
[Optochiasmatic tuberculomas as a paradoxical reaction to treatment for meningeal tuberculosis]. Revista de neurologia, 2018, Apr-16, Volume: 66, Issue:8 Topics: Adult; Antitubercular Agents; Brain Infarction; Diagnostic Errors; Disease Progression; Drug Resistance, Microbial; Drug Substitution; Ethambutol; Female; Host-Pathogen Interactions; Humans; Isoniazid; Magnetic Resonance Imaging; Meningitis, Viral; Moxifloxacin; Mycobacterium tuberculosis; Neuroimaging; Optic Chiasm; Paresis; Prednisone; Pyrazinamide; Rifampin; Thalamus; Tuberculoma; Tuberculosis, Meningeal; Vision Disorders	2018
Moxifloxacin Replacement in Contemporary Tuberculosis Drug Regimens Is Ineffective against Persistent Mycobacterium tuberculosis in the Cornell Mouse Model. Antimicrobial agents and chemotherapy, 2018, Volume: 62, Issue:7 Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Therapy, Combination; Ethambutol; Female; Isoniazid; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Moxifloxacin; Mycobacterium tuberculosis; Recurrence; Tuberculosis, Pulmonary	2018
Toxicity associated with tuberculosis chemotherapy in the REMoxTB study. BMC infectious diseases, 2018, 07-11, Volume: 18, Issue:1 Topics: Adult; Antitubercular Agents; Clinical Protocols; Ethambutol; Female; HIV Seropositivity; Humans; Incidence; Isoniazid; Male; Moxifloxacin; Treatment Outcome; Tuberculosis, Pulmonary	2018
Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling. Antimicrobial agents and chemotherapy, 2018, Volume: 62, Issue:12 Topics: Antitubercular Agents; Clofazimine; Colony Count, Microbial; Computer Simulation; Diarylquinolines; Dose-Response Relationship, Drug; Drug Dosage Calculations; Drug Resistance, Bacterial; Drug Therapy, Combination; Ethambutol; Host-Pathogen Interactions; Humans; Immunity, Innate; Isoniazid; Kanamycin; Macrophages; Microbial Sensitivity Tests; Models, Statistical; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Prothionamide; Pyrazinamide; Time Factors; Tuberculosis, Multidrug-Resistant	2018
Transformation Morphisms and Time-to-Extinction Analysis That Map Therapy Duration From Preclinical Models to Patients With Tuberculosis: Translating From Apples to Oranges. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018, 11-28, Volume: 67, Issue:suppl_3 Topics: Antitubercular Agents; Clinical Trials as Topic; Drug Discovery; Drug Evaluation, Preclinical; Ethambutol; Humans; Isoniazid; Models, Biological; Moxifloxacin; Mycobacterium tuberculosis; Recurrence; Sputum; Tuberculosis	2018
Microbiology (Reading, England), 2020, Volume: 166, Issue:2 Topics: Antitubercular Agents; Bacterial Proteins; Drug Resistance, Bacterial; Drug Tolerance; Ethambutol; Genome, Bacterial; Hydroxyl Radical; Isoniazid; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium smegmatis; Mycobacterium tuberculosis; Oxidation-Reduction; Oxidative Stress	2020
Successful Use of Rifamycin-Sparing Regimens for the Treatment of Active Tuberculosis in Lung Transplant Recipients. Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2021, Volume: 19, Issue:4 Topics: Ethambutol; Humans; Isoniazid; Lung; Lung Transplantation; Moxifloxacin; Pyrazinamide; Rifamycins; Transplant Recipients; Treatment Outcome; Tuberculosis	2021
Effectiveness of Shorter Treatment Regimen in Multidrug-Resistant Tuberculosis Patients in Pakistan: A Multicenter Retrospective Record Review. The American journal of tropical medicine and hygiene, 2021, 03-15, Volume: 104, Issue:5 Topics: Adult; Amikacin; Antitubercular Agents; Clofazimine; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Ethambutol; Ethionamide; Female; Humans; Isoniazid; Lost to Follow-Up; Male; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Pakistan; Pyrazinamide; Retrospective Studies; Survival Analysis; Treatment Failure; Tuberculosis, Multidrug-Resistant	2021
Genetic Determinants of Intrinsic Antibiotic Tolerance in Mycobacterium avium. Microbiology spectrum, 2021, 10-31, Volume: 9, Issue:2 Topics: Anti-Bacterial Agents; Clarithromycin; DNA Transposable Elements; Drug Therapy, Combination; Drug Tolerance; Ethambutol; Humans; Moxifloxacin; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Rifabutin	2021
Use of Whole-Genome Sequencing to Predict Microbiology spectrum, 2022, 04-27, Volume: 10, Issue:2 Topics: Amikacin; Aminosalicylic Acid; Antitubercular Agents; China; Cycloserine; Drug Resistance; Ethambutol; Ethionamide; Humans; Isoniazid; Kanamycin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Rifampin; Streptomycin; Tuberculosis, Multidrug-Resistant	2022
Prediction of Mycobacterium tuberculosis drug resistance by nucleotide MALDI-TOF-MS. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2022, Volume: 121 Topics: Amikacin; Antitubercular Agents; China; Drug Resistance; Ethambutol; Humans; Isoniazid; Kanamycin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Nucleotides; Ofloxacin; Rifampin; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Streptomycin; Tuberculosis, Lymph Node	2022
A case of ascetic fluid Mycobacterium aubagnense infection in a patient with severe peritoneal effusion. BMC infectious diseases, 2023, Feb-07, Volume: 23, Issue:1 Topics: Ascites; Ascitic Fluid; Diuretics; Ethambutol; Humans; Isoniazid; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria	2023
Genotypic and phenotypic comparison of drug resistance profiles of clinical multidrug-resistant Mycobacterium tuberculosis isolates using whole genome sequencing in Latvia. BMC infectious diseases, 2023, Sep-28, Volume: 23, Issue:1 Topics: Amikacin; Antitubercular Agents; Capreomycin; Drug Resistance, Multiple, Bacterial; Ethambutol; Ethionamide; Humans; Isoniazid; Kanamycin; Latvia; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant; Whole Genome Sequencing	2023
Protein binding investigation of first-line and second-line antituberculosis drugs. International journal of antimicrobial agents, 2023, Volume: 62, Issue:6 Topics: Antitubercular Agents; Ethambutol; Humans; Isoniazid; Levofloxacin; Linezolid; Moxifloxacin; Protein Binding; Pyrazinamide; Rifampin; Tuberculosis	2023